Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG

Food and Chemical Toxicology

Volumn 84, Issue , 2015, Pages 125-132

  Cerezo Guisado, María Isabel ^a,b   Zur, Rafal ^a   Lorenzo, María Jesús ^b   Risco, Ana ^a   Martín Serrano, Miguel A ^a   Alvarez Barrientos, Alberto ^b   Cuenda, Ana ^a   Centeno, Francisco ^b  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Akt; Apoptosis; Colon cancer; EGCG; ERK; P38 p38

Indexed keywords

EPIGALLOCATECHIN GALLATE; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYPHENOL; PROTEIN KINASE B; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CATECHIN; ISOENZYME; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TEA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; SIGNAL TRANSDUCTION; TEA; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMICALLY INDUCED; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FOOD HANDLING; GENETICS; HEK293 CELL LINE; METABOLISM; OSMOLARITY; PHOSPHORYLATION; PROTEIN PROCESSING; RNA INTERFERENCE; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; FOOD HANDLING; HEK293 CELLS; HUMANS; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; OSMOLAR CONCENTRATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; TEA;

EID: 84940386121     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2015.08.017     Document Type: Article

References (30)

1. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
2. Cerezo-Guisado M.I., del Reino P., Remy G., Kuma Y., Arthur J.S., Gallego-Ortega D., Cuenda A. Evidence of p38gamma and p38delta involvement in cell transformation processes. Carcinogenesis 2011, 32:1093-1099.
3. Chen C., Shen G., Hebbar V., Hu R., Owuor E.D., Kong A.N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 2003, 24:1369-1378.
4. Chen Z.P., Schell J.B., Ho C.T., Chen K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998, 129:173-179.
5. Criado G., Risco A., Alsina-Beauchamp D., Perez-Lorenzo M.J., Escos A., Cuenda A. Alternative p38 MAPKs are essential for collagen-induced arthritis. Arthritis Rheumatol. 2014, 66:1208-1217.
6. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429:403-417.
7. Cuenda A., Cohen P., Buee-Scherrer V., Goedert M. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 1997, 16:295-305.
8. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 2007, 1773:1358-1375.
9. Del Reino P., Alsina-Beauchamp D., Escos A., Cerezo-Guisado M.I., Risco A., Aparicio N., Zur R., Fernandez-Estevez M., Collantes E., Montans J., Cuenda A. Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38gamma and p38delta, linking inflammation and cancer in colitis-associated colon cancer. Cancer Res. 2014, 74:6150-6160.
10. Goedert M., Cuenda A., Craxton M., Jakes R., Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J. 1997, 16:3563-3571.
11. Jemal A., Center M.M., Ward E., Thun M.J. Cancer occurrence. Methods Mol. Biol. 2009, 471:3-29.
12. Kuma Y., Sabio G., Bain J., Shpiro N., Marquez R., Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 2005, 280:19472-19479.
13. Kyriakis J.M., Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 2012, 92:689-737.
14. Liu S., Wang X.J., Liu Y., Cui Y.F. PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am. J. Chin. Med. 2013, 41:629-642.
15. Park S.Y., Lee Y.-K., Kim Y.-M., Park O.J., Shin J.-I. Control of AMP-activated protein kinase, akt, and mTOR in EGCG-treated HT-29 colon cancer cells. Food Sci. Biotechnol. 2013, 22:147-151.
16. Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A., Chen G. p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response. J. Biol. Chem. 2007, 282:31398-31408.
17. Risco A., Cuenda A. New insights into the p38gamma and p38delta MAPK pathways. J. Signal Transduct. 2012, 2012:520289.
18. Risco A., del Fresno C., Mambol A., Alsina-Beauchamp D., MacKenzie K.F., Yang H.T., Barber D.F., Morcelle C., Arthur J.S., Ley S.C., Ardavin C., Cuenda A. p38gamma and p38delta kinases regulate the toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11200-11205.
19. Schindler E.M., Hindes A., Gribben E.L., Burns C.J., Yin Y., Lin M.H., Owen R.J., Longmore G.D., Kissling G.E., Arthur J.S., Efimova T. p38delta mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res. 2009, 69:4648-4655.
20. Shankar S., Marsh L., Srivastava R.K. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol. Cell Biochem. 2013, 372:83-94.
21. Shimizu M., Shirakami Y., Sakai H., Yasuda Y., Kubota M., Adachi S., Tsurumi H., Hara Y., Moriwaki H. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem. Biol. Interact. 2010, 185:247-252.
22. Siddiqui I.A., Adhami V.M., Afaq F., Ahmad N., Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J. Cell Biochem. 2004, 91:232-242.
23. Siddiqui I.A., Malik A., Adhami V.M., Asim M., Hafeez B.B., Sarfaraz S., Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008, 27:2055-2063.
24. Siegelin M.D., Habel A., Gaiser T. Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci. Lett. 2008, 448:161-165.
25. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82:1807-1821.
26. Stangl V., Dreger H., Stangl K., Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res. 2007, 73:348-358.
27. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat. Rev. Genet. 2009, 10:353-358.
28. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9:429-439.
29. Zhang T., Inesta-Vaquera F., Niepel M., Zhang J., Ficarro S.B., Machleidt T., Xie T., Marto J.A., Kim N., Sim T., Laughlin J.D., Park H., LoGrasso P.V., Patricelli M., Nomanbhoy T.K., Sorger P.K., Alessi D.R., Gray N.S. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 2012, 19:140-154.
30. Zhang X., Tang N., Hadden T.J., Rishi A.K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 2011, 1813:1978-1986.